TCM network pharmacology: new perspective integrating network target with artificial intelligence and multi-modal multi-omics technologies

Abstract

Traditional Chinese medicine (TCM) demonstrates distinctive advantages in disease prevention and treatment. However, analyzing its biological mechanisms through the modern medical research paradigm of “single drug, single target” presents significant challenges due to its holistic approach. Network pharmacology and its core theory of network targets connect drugs and diseases from a holistic and systematic perspective based on biological networks, overcoming the limitations of reductionist research models and showing considerable value in TCM research. Recent integration of network target computational and experimental methods with artificial intelligence (AI) and multi-modal multi-omics technologies has substantially enhanced network pharmacology methodology. The advancement in computational and experimental techniques provides complementary support for network target theory in decoding TCM principles. This review, centered on network targets, examines the progress of network target methods combined with AI in predicting disease molecular mechanisms and drug-target relationships, alongside the application of multi-modal multi-omics technologies in analyzing TCM formulae, syndromes, and toxicity. Looking forward, network target theory is expected to incorporate emerging technologies while developing novel approaches aligned with its unique characteristics, potentially leading to significant breakthroughs in TCM research and advancing scientific understanding and innovation in TCM.

Keywords

Network pharmacology / Traditional Chinese medicine / Network target / Artificial intelligence / Multi-modal / Multi-omics

References

[1] Li S. Possible correlation between TCM syndromes and molecular network regulation mechanism. Sci Technol Prog Soc Econ Dev Facing 21st Century. 1999;1:1.

[2] Li S, Wang YY, Ji L, et al. A discussion and case study of complexities in traditional Chinese medicine. J Syst Simul. 2002; 14(11):1429-1431. https://doi.org/10.16182/j.cnki.joss.2002.11.007.

[3] Li S, Zhang ZQ, Wu LJ, et al. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007; 1(1):51-60. https://doi.org/10.1049/iet-syb:20060032.

[4] Li S. Framework and practice of network-based studies for Chinese herbal formula. J Integr Med. 2007; 5(5):489-493. https://doi.org/10.3736/jcim20070501.

[5] Hopkins AL. Network pharmacology. Nat Biotechnol. 2007; 25(10):1110-1111. https://doi.org/10.1038/nbt1007-1110.

[6] Li S. Network target: a starting point for traditional Chinese medicine network pharmacology. Chin J Chin Mater Med. 2011; 36(15):2017-2020. https://doi.org/10.4268/cjcmm20111502.

[7] Li S. Mapping ancient remedies: applying a network approach to traditional Chinese medicine. Science. 2015; 350(6262S):S72-S74.

[8] Lai XX, Wang X, Hu YJ, et al. Editorial: network pharmacology and traditional medicine. Front Pharmacol. 2020;11:1194. https://doi.org/10.3389/fphar.2020.01194.

[9] Wang ZY, Wang X, Zhang DY, et al. Traditional Chinese medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance. Chin J Chin Mater Med. 2022; 47(1):7-17. https://doi.org/10.19540/j.cnki.cjcmm.20210914.702.

[10] Li S.Network pharmacology evaluation method guidance-draft. World J Tradit Chin Med. 2021; 7(1):146-154. https://doi.org/10.4103/wjtcm.wjtcm_11_21.

[11] Wu XB, Jiang R, Zhang MQ, et al. Network-based global inference of human disease genes. Mol Syst Biol; 2008; 4(1):189. https://doi.org/10.1038/msb.2008.27.

[12] Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS One. 2010; 5(7):e11764. https://doi.org/10.1371/journal.pone.0011764.

[13] Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol. 2011; 5(1):S10. https://doi.org/10.1186/1752-0509-5-10.

[14] Zhao SW, Li S. A co-module approach for elucidating drug-disease associations and revealing their molecular basis. Bioinformatics. 2012; 28(7):955-961. https://doi.org/10.1093/bioinformatics/bts057.

[15] Zhou WA, Yang K, Zeng JY, et al. FordNet: recommending traditional Chinese medicine formula via deep neural network integrating phenotype and molecule. Pharmacol Res. 2021;173:105752. https://doi.org/10.1016/j.phrs.2021.105752.

[16] Guo YC, Nie Q, MacLean AL, et al. Multiscale modeling of inflammation-induced tumorigenesis reveals competing oncogenic and oncoprotective roles for inflammation. Cancer Res. 2017; 77(22):6429-6441. https://doi.org/10.1158/0008-5472.CAN-17-1662.

[17] Zhang P, Yang M, Zhang Y, et al. Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer. Cell Rep. 2019; 27(6):1934-1947. https://doi.org/10.1016/j.celrep.2019.04.052.

[18] Hou S, Zhang P, Yang K, et al. Decoding multilevel relationships with the human tissue-cell-molecule network. Brief Bioinform. 2022; 23(5):bbac170. https://doi.org/10.1093/bib/bbac170.

[19] Li S.Intelligent and quantitative analysis methods and systems for drug network pharmacology based on network targets: China, 110648726. 2021-10-01.

[20] Buphamalai P, Kokotovic T, Nagy V, et al. Network analysis reveals rare disease signatures across multiple levels of biological organization. Nat Commun. 2021; 12(1):6306. https://doi.org/10.1038/s41467-021-26674-1.

[21] Ruiz C, Zitnik M, Leskovec J. Identification of disease treatment mechanisms through the multiscale interactome. Nat Commun. 2021; 12(1):1796. https://doi.org/10.1038/s41467-021-21770-8.

[22] Gan X, Shu ZX, Wang XY, et al. Network medicine framework reveals generic herb-symptom effectiveness of traditional Chinese medicine. Sci Adv. 2023; 9(43):eadh0215. https://doi.org/10.1126/sciadv.adh0215.

[23] Liang XJ, Li HY, Li S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang Pill as a case study. Mol Biosyst. 2014; 10(5):1014-1022. https://doi.org/10.1039/C3MB70507B.

[24] Guo YC, Bao C, Ma DC, et al. Network-based combinatorial CRISPR-Cas9 screens identify synergistic modules in human cells. ACS Synth Biol. 2019; 8(3):482-490. https://doi.org/10.1021/acssynbio.8b00237.

[25] Zhang SQ, Lai XX, Wang X, et al. Deciphering the pharmacological mechanisms of Guizhi-Fuling Capsule on primary dysmenorrhea through network pharmacology. Front Pharmacol. 2021;12:613104. https://doi.org/10.3389/fphar.2021.613104.

[26] Wang BY, Zhou WA, Zhang H, et al. Exploring the effect of Weifuchun Capsule on the toll-like receptor pathway mediated HES6 and immune regulation against chronic atrophic gastritis. J Ethnopharmacol. 2023;303:115930. https://doi.org/10.1016/j.jep.2022.115930.

[27] Xu HY, Li S, Liu JY, et al.Bioactive compounds from Huashi Baidu Decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci U S A. 2023; 120(18):e2301775120. https://doi.org/10.1073/pnas.2301775120.

[28] Wang BY, Zhang DF, Zhang TY, et al. Uncovering the mechanisms of Yi Qi Tong Qiao Pill in the treatment of allergic rhinitis based on network target analysis. Chin Med. 2023;18:88. https://doi.org/10.1186/s13020-023-00781-1.

[29] Li S, Lu AP, Wang YY, et al. Suppressive effects of a Chinese herbal medicine Qing-Luo-Yin extract on the angiogenesis of collagen-induced arthritis in rats. Am J Chin Med. 2003; 31(5):713-720. https://doi.org/10.1142/S0192415X03001430.

[30] Huang YZ, Li S. Detection of characteristic sub pathway network for angiogenesis based on the comprehensive pathway network. BMC Bioinformatics. 2010; 11(1):S32. https://doi.org/10.1186/1471-2105-11-32.

[31] Li Y, Wang X, Yang Z, et al. A new approach for optimizing empirical prescriptions of famous physicians based on network target: taking Qingluo Decoction as an example. Chin J Chin Mater Medica. 2022; 47(19):5264-5273. https://doi.org/10.19540/j.cnki.cjcmm.20220613.704.

[32] Wu Y, Zhang FL, Yang K, et al. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. 2019; 47(D1):D1110-D1117. https://doi.org/10.1093/nar/gky1021.

[33] Zhang YQ, Wang N, Du X, et al. SoFDA: an integrated web platform from syndrome ontology to network-based evaluation of disease-syndrome-formula associations for precision medicine. Sci Bull. 2022; 67(11):1097-1101. https://doi.org/10.1016/j.scib.2022.03.013.

[34] Huang L, Wang Q, Duan QC, et al. TCMSSD: a comprehensive database focused on syndrome standardization. Phytomedicine. 2024; 128:155486. https://doi.org/10.1016/j.phymed.2024.155486.

[35] Li X, Ren J, Zhang W, et al. LTM-TCM: a comprehensive database for the linking of traditional Chinese medicine with modern medicine at molecular and phenotypic levels. Pharmacol Res. 2022; 178:106185. https://doi.org/10.1016/j.phrs.2022.106185.

[36] Liu XY, Liu JY, Fu BZ, et al. DCABM-TCM: a database of constituents absorbed into the blood and metabolites of traditional Chinese medicine. J Chem Inf Model. 2023; 63(15):4948-4959. https://doi.org/10.1021/acs.jcim.3c00365.

[37] Fang SS, Dong L, Liu L, et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 2021; 49(D1):D1197-D1206. https://doi.org/10.1093/nar/gkaa1063.

[38] Kim SK, Lee MK, Jang H, et al. TM-MC 2.0:an enhanced chemical database of medicinal materials in Northeast Asian traditional medicine. BMC Complement Med Ther. 2024; 24(1):40. https://doi.org/10.1186/s12906-023-04331-y.

[39] Zhang YQ, Li X, Shi YL, et al. ETCM v2.0: an update with comprehensive resource and rich annotations for traditional Chinese medicine. Acta Pharm Sin B. 2023; 13(6):2559-2571. https://doi.org/10.1016/j.apsb.2023.03.012.

[40] Yan DY, Zheng GH, Wang CC, et al. HIT 2.0: an enhanced platform for herbal ingredients’ targets. Nucleic Acids Res. 2022; 50(D1):D1238-D1243. https://doi.org/10.1093/nar/gkab1011.

[41] Wang XY, Yang K, Jia T, et al. KDGene: knowledge graph completion for disease gene prediction using interactional tensor decomposition. Brief Bioinform. 2024; 25(3):bbae161. https://doi.org/10.1093/bib/bbae161.

[42] Rai P, Jain A, Kumar S, et al. Literature mining discerns latent disease-gene relationships. Bioinformatics. 2024; 40(4):btae185. https://doi.org/10.1093/bioinformatics/btae185.

[43] Li Y, Guo ZH, Wang KQ, et al.End-to-end interpretable disease-gene association prediction. Brief Bioinform. 2023; 24(3):bbad118. https://doi.org/10.1093/bib/bbad118.

[44] Xiang J, Meng XM, Zhao YC, et al. HyMM: hybrid method for disease-gene prediction by integrating multiscale module structure. Brief Bioinform. 2022; 23(3):bbac072. https://doi.org/10.1093/bib/bbac072.

[45] Wang YY, Yang K, Shu ZX, et al.Network-based gene prediction for TCM symptoms. 2020 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). 2020;2847-2854.

[46] Dong BZ, Sun WD, Xu DL, et al. DAEMDA: a method with dual-channel attention encoding for miRNA-disease association prediction. Biomolecules. 2023; 13(10):1514. https://doi.org/10.3390/biom13101514.

[47] Ma MY, Na S, Zhang XL, et al. SFGAE: a self-feature-based graph autoencoder model for miRNA-disease associations prediction. Brief Bioinform. 2022; 23(5):bbac340. https://doi.org/10.1093/bib/bbac340.

[48] Theodoris CV, Xiao L, Chopra A, et al. Transfer learning enables predictions in network biology. Nature. 2023; 618(7965):616-624. https://doi.org/10.1038/s41586-023-06139-9.

[49] Cui HT, Wang C, Maan H, et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat Methods. 2024; 21(8):1470-1480. https://doi.org/10.1038/s41592-024-02201-0.

[50] Huang ZJ, Zhang P, Deng L. DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response. Bioinformatics. 2023; 39(39Suppl 1):i475-i483. https://doi.org/10.1093/bioinformatics/btad244.

[51] Zhao BW, Hu L, You ZH, et al. HINGRL: predicting drug-disease associations with graph representation learning on heterogeneous information networks. Brief Bioinform. 2022; 23(1):bbab515. https://doi.org/10.1093/bib/bbab515.

[52] Yang MY, Wu GY, Zhao QC, et al. Computational drug repositioning based on multi-similarities bilinear matrix factorization. Brief Bioinform. 2021; 22(4):bbaa267. https://doi.org/10.1093/bib/bbaa267.

[53] Xu XQ, Xuan P, Zhang TG, et al. Inferring drug-target interactions based on random walk and convolutional neural network. IEEE/ACM Trans Comput Biol Bioinform. 2022; 19(4):2294-2304. https://doi.org/10.1109/TCBB.2021.3066813.

[54] Wang XW, Wu CY, Zhang SD, et al. A novel deep learning segmentation model for organoid-based drug screening. Front Pharmacol. 2022;13:1080273. https://doi.org/10.3389/fphar.2022.1080273.

[55] Bian YM, Xie XQ. Artificial intelligent deep learning molecular generative modeling of Scaffold-focused and cannabinoid CB2 target-specific small-molecule sublibraries. Cells. 2022; 11(5):915. https://doi.org/10.3390/cells11050915.

[56] Pham TH, Qiu Y, Zeng JC, et al. A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing. Nat Mach Intell. 2021; 3(3):247-257. https://doi.org/10.1038/s42256-020-00285-9.

[57] Malik V, Kalakoti Y, Sundar D. Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. BMC Genomics. 2021; 22(1):214. https://doi.org/10.1186/s12864-021-07524-2.

[58] Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020; 181(2):475-483. https://doi.org/10.1016/j.cell.2020.04.001.

[59] Guo Y, Hu HT, Chen WB, et al. SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction. Brief Bioinform. 2024; 25(2):bbae015. https://doi.org/10.1093/bib/bbae015.

[60] Feng YH, Zhang SW, Feng YY, et al. A social theory-enhanced graph representation learning framework for multitask prediction of drug-drug interactions. Brief Bioinform. 2023; 24(1):bbac602. https://doi.org/10.1093/bib/bbac602.

[61] Yu H, Zhao SY, Shi JY. STNN-DDI: a substructure-aware tensor neural network to predict drug-drug interactions. Brief Bioinform. 2022; 23(4):bbac209. https://doi.org/10.1093/bib/bbac209.

[62] Lin SG, Wang YJ, Zhang LF, et al. MDF-SA-DDI: predicting drug-drug interaction events based on multi-source drug fusion, multi-source feature fusion and transformer self-attention mechanism. Brief Bioinform. 2022; 23(1):bbab421. https://doi.org/10.1093/bib/bbab421.

[63] Lin SG, Chen WZ, Chen GW, et al. MDDI-SCL: predicting multi-type drug-drug interactions via supervised contrastive learning. J Cheminformatics. 2022; 14(1):81. https://doi.org/10.1186/s13321-022-00659-8.

[64] He HH, Chen GX, Chen YCC. 3DGT-DDI: 3D graph and text based neural network for drug-drug interaction prediction. Brief Bioinform. 2022; 23(3):bbac134. https://doi.org/10.1093/bib/bbac134.

[65] Zhang Y, Qiu Y, Cui YX, et al. Predicting drug-drug interactions using multi-modal deep auto-encoders based network embedding and positive-unlabeled learning. Methods San Diego Calif. 2020; 179:37-46. https://doi.org/10.1016/j.ymeth.2020.05.007.

[66] Chen X, Liu XE, Wu J. GCN-BMP: investigating graph representation learning for DDI prediction task. Methods San Diego Calif. 2020; 179:47-54. https://doi.org/10.1016/j.ymeth.2020.05.014.

[67] Allesøe RL, Lundgaard AT, Hernández MR, et al. Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models. Nat Biotechnol. 2023; 41(3):399-408. https://doi.org/10.1038/s41587-022-01520-x.

[68] Kuenzi BM, Park J, Fong SH, et al. Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell. 2020; 38(5):672-684.e6. https://doi.org/10.1016/j.ccell.2020.09.014.

[69] Lin SG, Zhang GW, Wei DQ, et al. DeepPSE: prediction of polypharmacy side effects by fusing deep representation of drug pairs and attention mechanism. Comput Biol Med. 2022;149:105984. https://doi.org/10.1016/j.compbiomed.2022.105984.

[70] Galeano D, Li ST, Gerstein M, et al. Predicting the frequencies of drug side effects. Nat Commun. 2020; 11(1):4575. https://doi.org/10.1038/s41467-020-18305-y.

[71] Lu YY, Li MY, Zhou QM, et al. Dynamic network biomarker analysis and system pharmacology methods to explore the therapeutic effects and targets of Xiaoyaosan against liver cirrhosis. J Ethnopharmacol. 2022;294:115324. https://doi.org/10.1016/j.jep.2022.115324.

[72] Wang XL, He QY, Chen Q, et al. Network pharmacology combined with metabolomics to study the mechanism of Shenyan Kangfu Tablets in the treatment of diabetic nephropathy. J Ethnopharmacol. 2021;270:113817. https://doi.org/10.1016/j.jep.2021.113817.

[73] Chen YT, Li KP, Zhao H, et al. Integrated lipidomics and network pharmacology analysis to reveal the mechanisms of berberine in the treatment of hyperlipidemia. J Transl Med. 2022; 20(1):412. https://doi.org/10.1186/s12967-022-03623-0.

[74] Liu TL, Bai M, Liu MN, et al. Novel synergistic mechanism of 11-keto-β-boswellic acid and Z-guggulsterone on ischemic stroke revealed by single-cell transcriptomics. Pharmacol Res. 2023;193:106803. https://doi.org/10.1016/j.phrs.2023.106803.

[75] Wang RK, Yang TY, Feng Q, et al. Integration of network pharmacology and proteomics to elucidate the mechanism and targets of traditional Chinese medicine Biyuan Tongqiao Granule against allergic rhinitis in an ovalbumin-induced mice model. J Ethnopharmacol. 2024;318:116816. https://doi.org/10.1016/j.jep.2023.116816.

[76] Yu F, Yu Y, Tian SS, et al. Quantitative proteomics reveals Shexiang Baoxin Pill exerts cardioprotective effects by preserving energy metabolism in a rat model of myocardial infarction. J Ethnopharmacol. 2021;266:113460. https://doi.org/10.1016/j.jep.2020.113460.

[77] Ye J, Huang F, Zeng HW, et al. Multi-omics and network pharmacology study reveals the effects of Dengzhan Shengmai Capsule against neuroinflammatory injury and thrombosis induced by ischemic stroke. J Ethnopharmacol. 2023;305:116092. https://doi.org/10.1016/j.jep.2022.116092.

[78] Zhao P, Li JS, Yang LP, et al. Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen Formula for the treatment of chronic obstructive pulmonary disease. Mol Med Rep. 2018; 17(4):5247-5257. https://doi.org/10.3892/mmr.2018.8480.

[79] Ma C, Zhao J, Zheng GY, et al. Qijiao Shengbai Capsule alleviated leukopenia by interfering leukotriene pathway: integrated network study of multi-omics. Phytomedicine. 2024;128:155424. https://doi.org/10.1016/j.phymed.2024.155424.

[80] Li S, Wang R, Zhang Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am J Chin Med. 2006; 34(6):937-947. https://doi.org/10.1142/S0192415X06004417.

[81] Wang X, Wu M, Lai XX, et al. Network pharmacology to uncover the biological basis of spleen qi deficiency syndrome and herbal treatment. Oxid Med Cell Longev. 2020;2020:2974268. https://doi.org/10.1155/2020/2974268.

[82] Wang YY, Sun YP, Yang BY, et al. Integrate metabolomics strategy and target prediction to reveal the ameliorate effect of four typical “cold” property herbs on hyperthyroidism rats. J Ethnopharmacol. 2023;301:115772. https://doi.org/10.1016/j.jep.2022.115772.

[83] Lu YY, Zhou CG, Zhu MD, et al. Traditional Chinese medicine syndromes classification associates with tumor cell and microenvironment heterogeneity in colorectal cancer: a single cell RNA sequencing analysis. Chin Med. 2021; 16(1):133. https://doi.org/10.1186/s13020-021-00547-7.

[84] Ding ZH, Chen WJ, Wu H, et al. Integrative network fusion-based multi-omics study for biomarker identification and patient classification of rheumatoid arthritis. Chin Med. 2023; 18(1):48. https://doi.org/10.1186/s13020-023-00750-8.

[85] Wu GS, Zhao J, Zhao J, et al. Exploring biological basis of syndrome differentiation in coronary heart disease patients with two distinct syndromes by integrated multi-omics and network pharmacology strategy. Chin Med. 2021; 16(1):109. https://doi.org/10.1186/s13020-021-00521-3.

[86] Fan XH, Zhao XP, Jin YC, et al. Network toxicology and its application to traditional Chinese medicine. Chin J Chin Mater Med. 2011; 36(21):2920-2922. https://doi.org/10.4268/cjcmm20112104.

[87] Liu CX, Zhang CN, Wang WX, et al. Integrated metabolomics and network toxicology to reveal molecular mechanism of celastrol induced cardiotoxicity. Toxicol Appl Pharmacol. 2019;383:114785. https://doi.org/10.1016/j.taap.2019.114785.

[88] Ge JC, Qian Q, Gao YH, et al. Toxic effects of tripterygium glycoside tablets on the reproductive system of male rats by metabolomics, cytotoxicity, and molecular docking. Phytomedicine. 2023;114:154813. https://doi.org/10.1016/j.phymed.2023.154813.

[89] Jiang HY, Gao HY, Li J, et al. Integrated spatially resolved metabolomics and network toxicology to investigate the hepatotoxicity mechanisms of component D of Polygonum multiflorum Thunb. J Ethnopharmacol. 2022;298:115630. https://doi.org/10.1016/j.jep.2022.115630.

[90] Kong J, Kui HQ, Tian Y, et al. Nephrotoxicity assessment of podophyllotoxin-induced rats by regulating PI3K/Akt/mTOR-Nrf2/HO1 pathway in view of toxicological evidence chain (TEC) concept. Ecotoxicol Environ Saf. 2023;264:115392. https://doi.org/10.1016/j.ecoenv.2023.115392.

[91] Ren JL, Dong H, Han Y, et al. Network pharmacology combined with metabolomics approach to investigate the protective role and detoxification mechanism of Yunnan Baiyao Formulation. Phytomedicine. 2020;77:153266. https://doi.org/10.1016/j.phymed.2020.153266.

[92] Yang CM, Zhu SB, Chen YL, et al. Flavonoid 4,4′-dimethoxychalcone suppresses cell proliferation via dehydrogenase inhibition and oxidative stress aggravation. Free Radic Biol Med. 2021; 175:206-215. https://doi.org/10.1016/j.freeradbiomed.2021.09.002.

[93] Yang Z, Zhang XW, Zhuo FF, et al. Allosteric activation of transglutaminase 2 via inducing an “open” conformation for osteoblast differentiation. Adv Sci. 2023; 10(18):2206533. https://doi.org/10.1002/advs.202206533.

[94] Qiao HH, Wang F, Xu RG, et al. An efficient and multiple target transgenic RNAi technique with low toxicity in Drosophila. Nat Commun. 2018; 9(1):4160. https://doi.org/10.1038/s41467-018-06537-y.